Article summary
In a dedicated coronavirus (COVID-19) workshop, international medical regulators, under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), discussed how data elaborated in clinical practice could complement evidence from clinical trials to develop treatment for coronavirus. Participants recognised the need to combine observational studies of real-world data with clinical trials to improve regulatory processes for development of treatment and prevention of the virus and to address gaps in knowledge.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial